Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Haemophilia

Volumn 20, Issue 1, 2014, Pages 65-72

  Antunes, S V ^a   Tangada, S ^b   Stasyshyn, O ^c   Mamonov, V ^d   Phillips, J ^e   Guzman Becerra, N ^b   Grigorian, A ^b   Ewenstein, B ^b   Wong, W Y ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^d Department of Reconstructive Orthopedic Surgery for Hemophilia Patients ^*  (Russian Federation)

^e WELLINGTON HOSPITAL   (New Zealand)

Author keywords

FEIBA; Haemophilia A B; Inhibitors; On demand; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ABDOMINAL BLEEDING; ADOLESCENT; ADULT; ARTERIOSCLEROSIS; ARTHROPATHY; ARTICLE; BLEEDING; CATHETER REMOVAL; CHILD; CHOLECYSTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMUR NECK FRACTURE; HEADACHE; HEMARTHROSIS; HEMATOMA; HEMATURIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERTENSIVE CRISIS; HYPOTENSION; INCIDENCE; INFECTION; JOINT; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE BLEEDING; NANOFILTER; ON DEMAND REGIMEN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

FEIBA; HAEMOPHILIA A/B; INHIBITORS; ON-DEMAND; PROPHYLAXIS;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890855644     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12246     Document Type: Article

References (28)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al., Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-14.
2. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
3. National Hemophilia Foundation. Recommendation concerning prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). National Hemophilia Foundation (NHF), 2007; Report No.: MASAC 179.
4. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
5. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
6. Valentino LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 2006; 12(Suppl. 5): 26-31.
7. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA©) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
8. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
9. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
10. Hoots WK, Ebbesen LS, Konkle BA et al., Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
11. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
12. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
13. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
14. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
15. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-9.
16. Gringeri A, Mantovani L, Mackensen SV. Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia 2006; 12(Suppl. 3): 22-9.
17. von Mackensen S, Bullinger M, Haemo-Qol Group. Development and testing of an instrument to assess the quality of life of children with haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10(Suppl. 1): 17-25.
18. Choiniere M, Amsel R. A visual analogue thermometer for measuring pain intensity. J Pain Symptom Manage 1996; 11: 299-311.
19. Beyer JE, Aradine CR. Patterns of pediatric pain intensity: a methodological investigation of a self-report scale. Clin J Pain 1987; 3: 130-41.
20. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-32.
21. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 5: 70.
22. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
23. Escuriola Ettingshausen C, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16: 90-100.
24. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
25. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin free recombinant factor VIII (rAHF-PFM): pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
26. Shapiro A, Gruppo R, Pabinger I et al. Integrated analysis of safety and efficacy of a plasma and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther 2009; 9: 273-83.
27. Valentino LA, Mamonov V, Hellmann A et al., The Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
28. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.